

ISSN 2459 - 1777



BEYOGLU EYE JOURNAL



Volume 9 Issue 3 Year 2024

TUBITAK TR INDEX, TURK MEDLINE,
TURKIYE CITATION INDEX, EBSCO, PUBMED,
PUBMED CENTRAL, PROQUEST, DOAJ,
RESEARCH4LIFE, HINARI, SCOPE DATABASE,
SCOPUS, GALE, IDEALONLINE INDEX AND
ASIAN SCIENCE CITATION INDEX.

www.beyoglu-eye.com



Ozurdex®

(dexamethasone intravitreal implant) 0.7mg

Diyabetik maküler ödem ve retina ven tıkanıklıklarında retinada oluşan inflamasyon, ödem ve retina kalınlaşmalarına karşı **Ozurdex®**'e geçin, hastanızın görüşünü iyileştirin.¹

OZURDEX®'E ERKEN GEÇİŞLE

GÖZLE GÖRÜLÜR ETKİ



Ozurdex
Kısa Ürün Bilgisine
erişmek için

abbvie

ABBVIE TIBBİ İLAÇLAR SAN. VE TİC. LTD. ŞTİ.
Mersis No: 4737376165553262
Adres: Barbaros Mah. Begonya Sk. Nidakule Ataşehir Battı Blok No:1
İç Kapı No: 33 34746 Ataşehir / İstanbul
Telefon: +90 216 633 21 42 E-mail: bilgi@abbvie.com

Hayat gözlerimizden
daha fazlasını bekliyor

MAX konfor. **MAX** netlik.*¹

*ACUVUE® OASYS 1-Day ile karşılaştırıldığında.

YENİ

**ACUVUE® OASYS MAX 1-DAY
KONTAKT LENS**

İki yeni teknolojinin benzeri
görülmemiş kombinasyonu¹:

**TEARSTABLE™
TEKNOLOJİSİ**

+

**OPTIBLUE™
IŞIK FİLTRESİ**



Görselleştirme amaçlı kullanılmıştır.

Multifokal için de mevcut

1. JJV arşiv verisi, 2022. CSM Subjective Responses ACUVUE® OASYS MAX 1-Day Contact Lenses - Retrospective Meta-analysis.
ACUVUE®, ACUVUE® OASYS MAX 1-Day ve ACUVUE® OASYS MAX 1-Day MULTIFOCAL, Johnson & Johnson'ın ticari markalarıdır.

ACUVUE®

DHA,dan zengin Omega 3,
Maquiberry ve Zerdeçal Ekstresi ile

DESTEĞİ MAX'LAYIN



İçindekiler*

Günlük Alım Dozu (2 kapsül) Etken Madde Miktarı

Balık Yağı	921,4 mg
•Omega-3	742 mg
•DHA	584 mg
Zeaxantin	2 mg
Lutein	10 mg
Maquiberry ekstresi	30 mg
Zerdeçal ekstresi	20 mg
Vitamin C	180 mg
Vitamin E	30 mg α-TE
Çinko	15 mg



*Tarım ve Orman Bakanlığınca onaylı ürün dosyası

BAUSCH + LOMB

Bimatocare

Bimatoprost %0.01

**TÜRKİYE'DE İLK VE TEK
PREZERVANSIZ BİMATOPROST**



prezervansız ¹

güçlü etki ²

**oküler yüzeyi
korur ³**

**ilk basamak
Tedavi ³**

**multidoz
şişe ¹**

Daha geniş bilgi ve Kısa Ürün Bilgisi için firmamıza başvurunuz.

DEVA HOLDİNG Halkalı Merkez Mah. Basın Ekspres Cad. No:1 34303 Küçükçekmece/İSTANBUL Tel: (0212) 444 DEVA (3382)

SABA Halkalı Merkez Mah. Basın Ekspres Cad. No:1 Kat:1 34303 Küçükçekmece/İSTANBUL Tel: (0212) 444 DEVA (3382)

24DVA0920BMT009



Bimatocare KÜB için
QR kodu okutunuz.

EastPharma



Ref.: 1) Bimatocare KÜB

2) Schuster, Alexander K., et al. "The diagnosis and treatment of glaucoma." Deutsches Ärzteblatt International 117.13 (2020)

3) European Glaucoma Society, TERMINOLOGY and GUIDELINES for GLAUCOMA 2021



www.deva.com.tr www.sabailac.com.tr

DEVA Holding

BRIMOLIX

Brimonidin Tartarat

%0,15

PREZERVAN İÇERMEZ*



Sağlık meslek mensupları için hazırlanmıştır.



QR KODU OKUTARAK
BRIMOLIX
KISA ÜRÜN BİLGİSİNE
ULAŞABİLİRSİNİZ.

www.vemilac.com

Referanslar: * Brimolix KÜB.

BRM / B2024-0201

Adrussen PLUS

İÇERİK	MİKTAR
Astaksantin	4 mg
Lutein	10 mg
Zeaksantin	2 mg
EPA	185 mg
DHA	140 mg
C Vitamini	60 mg
E Vitamini	30 mg
Çinko	12,5 mg
Bakır	1 mg





**BRİMOGUT,
PREZERVANA BAĞLI
YAN ETKİ OLUŞMASINI
ÖNLER.¹**

**BRİMOGUT,
GLOKOM TEDAVİSİNDE
NÖROPROTEKTİF ETKİ
SAĞLAR.²**

Referans: 1. JAENEN et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. European Journal of Ophthalmology / Vol. 17 no. 3, 2007 / pp. 341-349.
2. Wheeler et al. Role of Alpha-2 Agonists in Neuroprotection. SURVEY OF OPHTHALMOLOGY VOLUME 48 Suppl 1 APRIL 2005.

**bilim
İLAÇ**

**bilimsel
paydaş**

Ayrıntılı bilgi için firmamıza başvurunuz. www.bilimilac.com.tr



Brimogut
% 0.15 Brimonidin tartarat

MOXIDEXA

%0.5 Moksifloksasin / %0.1 Deksametazon
Steril Oftalmik Çözelti

Gözünüz Arkada Kalmasın

Oküler cerrahi sonrası inflamasyonu azaltır, enfeksiyon riskini düşürür.^{1,2}



KÜB bilgisi için
lütfen QR kodu
okutunuz.



1. Freitas LL et al. Curr Med Res Opin 2007;23(12):3123-30. 2. Moxidexa KÜB.

STABİLİTE BUDUR

Karşınızda

HYPEROVIT™
DUAL KESİ VİTREKTOMİ PROBU



- ⌘ Sürekli açık olan port ve CONSTELLATION Vision Sistem'in göz içi basınç (GİB) dengelemesi ile stabiliteyi artırmak^{1,2}
- ⌘ Tek bıçaklı problara benzer akış hızında, dakikada 20.000 kesi ile 25+G® ve 27+G® probları kullanarak pulsatil traksiyonu azaltmak³
- ⌘ Vitreus akışını iyileştirmek⁴
- ⌘ Eğimli uç ile doku düzlemine daha yakın erişim sağlamak⁵

İçin tasarlanmıştır.

Endikasyonlar, kontrendikasyonlar, uyarılar için lütfen ilgili ürünün kullanma talimatına, önemli ürün bilgileri için www.ifu.alcon.com sayfasına bakınız.

Referanslar: 1. Abulon DJ, Charles M, Charles DE. Globe stability during simulated vitrectomy with valved and non-valved trocar cannulas. Clin Ophthalmol. 2015;9:1745–1752. 2. Irannejad A, Tambat S, Abulon DJK. Retropulsion and mass flow of 27-gauge vitrectomy probes: comparison of dual-blade/flat-tipped probes and single-blade/beveled probes. Poster presented at: 18th Congress of the European Society of Retina Specialists; September 20–23, 2018; Vienna, Austria. 3. Alcon data on file. Alcon Laboratories, Inc; June 2018. 4. Alcon data on file. Alcon Laboratories, Inc; June 2018. 5. Alcon data on file. Alcon Laboratories, Inc; May 2017.

Alcon

TR-HV-2400001



Editor-in-Chief

Muhittin TASKAPILI, MD

University of Health Sciences, Beyoglu Eye Training and Research Hospital, Istanbul

Editor

Cigdem ALTAN, MD

University of Health Sciences, Beyoglu Eye Training and Research Hospital, Istanbul

Associate Editors

Pinar CAKAR OZDAL, MD

Ankara Ulucanlar Eye Training and Research Hospital, Ankara

Melda NURSAL YENEREL, MD

Haydarpaşa Numune Training and Research Hospital, Istanbul

Irfan PERENTE, MD

University of Health Sciences, Beyoglu Eye Training and Research Hospital, Istanbul

Afsun SAHİN

Department of Ophthalmology, Koc University, Istanbul

Yusuf YILDIRIM, MD

University of Health Sciences, Beyoglu Eye Training and Research Hospital, Istanbul

International Scientific Advisory Board

Iqbal Ike K. AHMED, MD

Prism Eye Institute, Mississauga, Ontario, Canada

Cagri G. BESIRLI, MD

Michigan Medicine Ophthalmology, Retina Clinic, Ann Arbor, MI, USA

Jean Deschênes, MD, FRCSC

McGill University, Ophthalmologist-in-Chief, McGill University Health Center, Montréal, Québec, Canada

Murat DOGRU, MD

Keio University, Department of Ophthalmology, Keio, Tokyo, Japan

Nina JOVANOVIĆ, MD

Canton Hospital Zenica, Ophthalmology Department, Zenica, Bosnia and Herzegovina

Sezen KARAKUS, MD

The Johns Hopkins Wilmer Eye Institute, Baltimore, United State of America

Ulugbek R. KARIMOV, MD

Sirdarya Regional Ophthalmic Hospital, Tashkent, Uzbekistan

Nazim ZAYNUTDINOV, MD

Tashkent Graduate Education Institute, Department of Eye Diseases, Tashkent, Uzbekistan

Statistical Editor

Nurdan COLAKOGLU

Department of Business Administration, Arel University Faculty of Economic and Administrative Sciences, Istanbul, Türkiye

Language Editor

Neslihan ONDER OZDEMİR, MD

Bursa Uludağ University, School of Foreign Languages, Bursa, Türkiye



Owner (Publisher): İstanbul: Beyoglu Göz Eğitim ve Arastırma Hastanesi
(Beyoglu Eye Journal)

Address: Bereketzade Cami Sokak No: 2 Beyoglu/Istanbul/Türkiye

Phone: +90 212 251 59 00

Fax: +90 212 245 09 48

E-mail: info@beyogluEye.com

Web: <https://beyogluGozeah.saglik.gov.tr>

Corporate Contributor (Publishing House): Kare Yayıncılık (Kare Publishing)

Address: Göztepe Mah. Fahrettin Kerim Gökay
Cad. No: 200 Da: 2, Göztepe, Kadıköy,
İstanbul, Türkiye

Phone: +90 216 550 61 11

Fax: +90 216 550 61 12

Web: www.karepb.com

E-mail: kare@karepb.com

Publications Coordinator: Eymen Iskender

Graphic Design: Beste Kurtcu

Beyoglu Eye Journal is indexed in TUBITAK TR Index, Turk Medline, Türkiye Citation Index, EBSCO, PubMed, PubMed Central, ProQuest, DOAJ, Research4Life, Hinari, Scopus Database, Scopus, GALE, Idealline index and Asian Science Citation Index.

Beyoglu Eye Journal is a peer-reviewed journal published triannually by the Beyoglu Eye Training and Research Hospital.

Materials published in the Journal is covered by copyright 2024 Beyoglu Eye Journal. All rights reserved.

This publication is printed on paper that meets the international standard ISO 9706:1994.

National Library of Medicine (USA) recommends the use of permanent, acid-free paper in the production of biomedical literature.

Yayın Turu: Uluslararası Sureli
Basım Tarihi: September 2024
Basım: Yıldırım Matbaacılık, İstanbul
Tel: +90 212 629 80 37



BEYOGLU EYE JOURNAL

National Scientific Advisory Board

Mutlu ACAR, MD
Department of Ophthalmology,
Yuksekk Ihtisas University, Liv
Hospital, Ankara, Türkiye

Banu ACIKALIN, MD
Istanbul University of Health
Sciences, Fatih Sultan Mehmet
SUAM, Istanbul, Türkiye

Alper AGCA, MD
Department of Ophthalmology,
World Eye Hospital, Istanbul, Türkiye

Serpil AKAR, MD
Department of Ophthalmology,
Başkent University, Istanbul, Türkiye

Funda Ebru Aksoy, MD
Department of Ophthalmology,
Beyoglu Training and Research
Hospital, Istanbul, Türkiye

Mehmet Numan ALP, MD
Department of Ophthalmology,
Dünya Göz Hospital, Ankara, Türkiye

Ceyhun ARICI, MD
Department of Ophthalmology,
Cerrahpaşa Faculty of Medicine,
Istanbul, Türkiye

Halil Ozgur ARTUNAY, MD
Department of Ophthalmology,
University of Health Sciences, Beyoglu
Eye Training and Research Hospital,
Istanbul, Türkiye

Burcu Kemer Atik, MD
Department of Ophthalmology,
Beyoglu Training and Research
Hospital, Istanbul, Türkiye

Sevcan Balci, MD
Department of Ophthalmology,
Haydarpaşa Numune Training and
Research Hospital, Istanbul, Türkiye

Muhammed BATUR, MD
Department of Ophthalmology,
Yüzüncü Yıl University Faculty of
Medicine, Van, Türkiye

Ozlem BUDAKOGLU, MD
Department of Ophthalmology, Binali
Yıldırım University, Erzincan, Türkiye

Ayşe BURCU, MD
Department of Ophthalmology,
Ankara Training and Research
Hospital, Ankara, Türkiye

Kübra SEREFOGLU CABUK, MD
Department of Ophthalmology,
University of Health Sciences, Çam
Sakura State Hospital, Istanbul,
Türkiye

Ali Bulent CANKAYA, MD
Department of Ophthalmology,
Hacettepe University Faculty of
Medicine, Ankara, Türkiye

Arzu TASKIRAN ÇOMEZ, MD
Department of Ophthalmology,
Okmeydanı Training and Research
Hospital, Istanbul, Türkiye

Cumali Değirmenci, MD
Department of Ophthalmology,
Dokuz Eylül University Faculty of
Medicine, İzmir, Türkiye

Ufuk ELGIN, MD
Department of Ophthalmology,
Ankara Ulucanlar Eye Training and
Research Hospital, Ankara, Türkiye

Muhsin ERASLAN, MD
Department of Ophthalmology,
Marmara University, Istanbul, Türkiye

M. Gürkan ERDOĞAN, MD
Department of Ophthalmology,
Istanbul University, Istanbul Faculty of
Medicine, Istanbul, Türkiye

Sezin OZDOĞAN ERKUL, MD
Department of Ophthalmology,
Istanbul University, Istanbul Faculty of
Medicine, Istanbul, Türkiye

Yasemin OZDAMAR EROL, MD
Department of Ophthalmology,
Ankara Ulucanlar Eye Training and
Research Hospital, Ankara, Türkiye

Birsen GOKYIGIT, MD
Department of Ophthalmology,
University of Health Sciences, Beyoglu
Eye Training and Research Hospital,
Istanbul, Türkiye

Hülya GUNGEL, MD
Department of Ophthalmology,
Health Sciences University, Istanbul
Training and Research Hospital,
Istanbul, Türkiye

Sirel GUR GUNGOR, MD
Department of Ophthalmology,
Başkent University, Istanbul, Türkiye

Kivanc GUNGOR, MD
Department of Ophthalmology,
Gaziantep University Faculty of
Medicine, Gaziantep, Türkiye

Serhat IMAMOĞLU, MD
Department of Ophthalmology,
Health Sciences University
Haydarpaşa Numune SUAM,
Istanbul, Türkiye

Sibel KADAYIFCILAR, MD
Department of Ophthalmology,
Hacettepe University, Ankara, Türkiye

Gamze OZTURK
KARABULUT, MD
Department of Ophthalmology,
University of Health Sciences, Beyoglu
Eye Training and Research Hospital,
Istanbul, Türkiye

Eyyüp Karahan, MD
Department of Ophthalmology, Doç.
Dr. Eyyüp Karahan Kliniği, Balıkesir,
Türkiye

Süleyman KAYNAK, MD
Department of Ophthalmology,
Dokuz Eylül University Faculty of
Medicine, İzmir, Türkiye

Ahmet KIRGIZ, MD
Department of Ophthalmology,
University of Health Sciences, Beyoglu
Eye Training and Research Hospital,
Istanbul, Türkiye

Tolga KOCATURK, MD
Department of Ophthalmology, Adnan
Menderes University, Aydın, Türkiye

Isil KUTLUTURK, MD
Department of Ophthalmology,
Beyoglu Training and Research
Hospital, Istanbul, Türkiye

Halit OGUZ, MD
Department of Ophthalmology,
Medeniyet University Faculty of
Medicine, Istanbul, Türkiye

Özay OZ, MD
Department of Ophthalmology,
Istanbul Yeni Yüzyıl University Faculty
of Medicine, Istanbul, Türkiye

Hakan OZDEMİR, MD
Department of Ophthalmology,
Bezmi Alem University Faculty of
Medicine, Istanbul, Türkiye

Altan Atakan OZKAN, MD
Department of Ophthalmology,
Çukurova University Faculty of
Medicine, Adana, Türkiye

Cemal Özsaygılı, MD
Department of Ophthalmology,
Kayseri City Hospital, Kayseri, Türkiye

Banu TURGUT OZTURK, MD
Department of Ophthalmology,
Selçuk University, Konya, Türkiye

Can OZTURKER, MD
Department of Ophthalmology,
Istanbul University, Istanbul Faculty of
Medicine, Istanbul, Türkiye

Melis PALAMAR, MD
Department of Ophthalmology,
Dokuz Eylül University Faculty of
Medicine, İzmir, Türkiye

Seren Pehlivanoglu, MD
Department of Ophthalmology,
University of Health Sciences, Beyoglu
Eye Training and Research Hospital,
Istanbul, Türkiye

Ali Osman SAATCI, MD
Department of Ophthalmology,
Dokuz Eylül University, Faculty of
Medicine, İzmir, Türkiye

Nihat Sayın, MD
Department of Ophthalmology,
Istanbul Kanuni Sultan Süleyman
Training and Research Hospital,
Istanbul, Türkiye

Ahmet Murat SARICI, MD
Department of Ophthalmology,
Istanbul University Cerrahpaşa
Faculty of Medicine, Istanbul, Türkiye

Emine MALKOC SEN, MD
Department of Ophthalmology,
Ulucanlar Training and Research
Hospital, Ankara, Türkiye

Mehmet Ali SEKEROGLU, MD
Department of Ophthalmology,
Ulucanlar Training and Research
Hospital, Ankara, Türkiye

Tülay SIMSEK, MD
Department of Ophthalmology,
Osmangazi University Faculty of
Medicine, Eskişehir, Türkiye

Tamer TAKMAZ, MD
Department of Ophthalmology,
Ankara City Hospital, Ankara, Türkiye

Betül TUGCU, MD
Department of Ophthalmology,
Bezmi Alem Vakıf University, Istanbul,
Türkiye

Semra AKKAYA TURHAN, MD
Department of Ophthalmology,
Marmara University School of
Medicine, Istanbul, Türkiye

Nurten UNLU, MD
Department of Ophthalmology,
University of Health Science Ankara
Health Application Research Center,
Ankara, Türkiye

Canan Asli UTINE, MD
Department of Ophthalmology,
Dokuz Eylül University Faculty of
Medicine, İzmir, Türkiye

Tekin YAŞAR, MD
Department of Ophthalmology,
University of Health Sciences, Beyoglu
Eye Training and Research Hospital,
Istanbul, Türkiye

Ozgur YALCINBAYIR, MD
Department of Ophthalmology,
Uludağ University, Bursa, Türkiye

Nilüfer YALCINDAG, MD
Department of Ophthalmology,
Ankara University Faculty of
Medicine, Ankara, Türkiye

Serpil YAZGAN, MD
Department of Ophthalmology,
İnönü University Faculty of Medicine,
Malatya, Türkiye

Ulviye YIGIT, MD
Department of Ophthalmology,
Health Sciences University Bakarköy
Sadi Konuk SUAM, Istanbul, Türkiye

Aysegül Mavi YILDIZ, MD
Department of Ophthalmology, Bursa
Retina Eye Hospital, Bursa, Türkiye

Burçin KEPEZ YILDIZ, MD
Department of Ophthalmology,
University of Health Sciences, Beyoglu
Eye Training and Research Hospital,
Istanbul, Türkiye

Suzan GUVEN YILMAZ, MD
Department of Ophthalmology, Ege
University Faculty of Medicine, İzmir,
Türkiye



Aim and Scope

The BEYOGLU EYE JOURNAL is an international periodical published triannually based on independent, unbiased, double-blinded and peer-review principles. Four issues are released every year in March, June, September, and December. The language of publication is English.

The BEYOGLU EYE JOURNAL aims to publish qualified and original clinical, experimental and basic research on ophthalmology at the international level. The journal's scope also covers editorial comments, reviews of innovations in medical education and practice, case reports, scientific letters, educational articles, letters to the editor, articles on publication ethics, technical notes, and reviews.

The target readership includes academic members, specialists, residents, and general practitioners working in the field of ophthalmology.

The editorial and publication processes of the journal are conducted in accordance with the guidelines of the International Committee of Medical Journal Editors (ICMJE), the World Association of Medical Editors (WAME), the Council of Science Editors (CSE), the European Association of Science Editors (EASE), and the Committee on Publication Ethics (COPE).

Beyoglu Eye Journal is indexed in TUBITAK TR Index (2016), Turk Medline (2017), Turkiye Citation Index (2017), EBSCO (2018), PubMed (2019), PubMed Central (2019), ProQuest (2020), DOAJ (2020), Research4Life (2020), Hinari (2020), Scope Database (2021), Scopus (January 2023), GALE (June 2023), Idealonline index (2024) and Asian Science Citation Index (ASCI) (2024).

It is the goal of the BEYOGLU EYE JOURNAL to be indexed in the Web of Science, SCI-Expanded and Index Medicus.

The requirements for submission of manuscripts and detailed information about the evaluation process are available in the published journal and also as 'Instructions for Authors' on the website (www.beyoglueye.com).

Statements and opinions expressed in the BEYOGLU EYE JOURNAL reflect the views of the author(s). All liability for the advertisements rests with the appropriate organization(s). The Beyoglu Eye Training and Research Hospital, the editor-in-chief and KARE PUBLISHING do not accept any responsibility for these articles and advertisements.

Subscriptions

Applications for subscriptions should be made to the editorial office.

Financial support and advertising

The revenue of the BEYOGLU EYE JOURNAL is derived from subscription charges and advertisements. Institutions wishing to place an advertisement in the printed version of the journal or on the webpage should contact KARE PUBLISHING.



Instructions for Authors

Submission of Manuscripts

This journal uses JournalAgent to peer-review manuscript submissions. Please read the guide for JournalAgent authors before making a submission. Complete guidelines for preparing and submitting your manuscript to this journal are provided below. (<https://www.journalagent.com/beyoglu/>)

All authors' ORCID numbers need to be submitted when creating an account for correspondence. To obtain an ORCID number, please visit: <https://orcid.org/>

Manuscripts must be submitted through the journal's website <http://www.journalagent.com/beyoglu/>. Paper manuscript submissions are not accepted. Full-length papers comprise the major part of each issue. Reviews are accepted for publication only at the invitation of the Editors.

It is the responsibility of the authors to ensure that the English used in their manuscript is correct, both grammatically and stylistically, before submission.

Beyoglu Eye Journal strives to publish papers of high quality regarding clinical research, epidemiology, anatomy, biophysics, biochemistry, developmental biology, microbiology, and immunology related to the eye and vision.

Publishing Ethics

The Editors and Kare Publishing are committed to upholding the highest academic, professional, legal, and ethical standards in the publication of this journal. To this end, we have adopted a set of guidelines, to which all submitting authors are expected to adhere, to assure integrity and ethical publishing for authors, reviewers, and editors.

The publisher, Kare Publishing, is a member of the Committee of Publications Ethics (COPE). COPE aims to provide a forum for publishers and editors of scientific journals to discuss issues related to the integrity of their work, including conflicts of interest, falsification and fabrication of data, ethical misconduct, unethical experimentation, inadequate patient consent, and authorship disputes. For more information on COPE please visit <http://publicationethics.org>.

Fees

There is no fee for article submission, article processing or publication.

Policy of Screening for Plagiarism

The manuscripts are scanned by the Publisher's Office using the iThenticate program for determination of plagiarism and non-ethical situations.

Open Access

Beyoglu Eye Journal is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.

Commons User Licenses

Creative Commons Attribution-NonCommercial (CC BY-NC) For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work, as long as they credit the author(s) and provided they do not alter or modify the article.

Length of Manuscripts: The maximum word count and illustrations including tables is:

Full Papers: 5000 words, 8 illustrations / tables

Case Reports: 3500 words, 5 illustrations / tables, max 6 authors

Short Communications: 1500 words, 4 illustrations / tables, max 2 authors

Reviews: 7000 words, 10 illustrations / tables

Case Reports: 4000 words, 8 illustrations / tables

Surgical Techniques: 4000 words, 8 illustrations / tables, max 3 authors

Authors who wish to contribute a review should first contact one of the editors-in-chief, Muhittin Taskapili (mutaskapili@gmail.com).

The journal accepts letters (not to exceed 750 words) only if they concern articles already published in Beyoglu Eye Journal. (max 2 authors)

Announcements of forthcoming meetings, courses, etc., may be published. The editors will also consider special issues containing papers on topics of focus or from a conference.

Each manuscript must be accompanied by a statement indicating that it has not been published elsewhere and that it has not been submitted simultaneously for publication elsewhere. Beyoglu Eye Journal follows the guidelines of the International Committee of Medical Journal Editors, which generally prohibits duplicate publication (<http://www.icmje.org/>). It is also the responsibility of the lead or corresponding author to indicate on the manuscript title page whether a commercial relationship existed in the form of financial support or personal financial interest. Financial support includes support from a for-profit company in the form of research funding.

Authors are responsible for obtaining permission to reproduce copyrighted material from other sources and are required to sign an agreement for the transfer of copyright to the publisher. As an author, you are required to secure permission if you want to reproduce any figure, table, or extract text from any other source. This applies to direct reproduction as well as "derivative reproduction" (such as when you have created a new figure or table which is derived substantially from a copyrighted source).

All accepted manuscripts, artwork, and photographs become the property of the publisher. All parts of the manuscript should be written in a clear font, such as Times New Roman or Arial, double-spaced, with margins of at least one inch on all sides. The main text and tables should be uploaded as Word documents. Do not include line numbers. Manuscript pages should be numbered consecutively throughout the paper.

Authors should provide a cover letter that includes the contact details of the corresponding author. Authors should briefly explain why their work is appropriate for Beyoglu Eye Journal.

Manuscript Structure

Submissions need to be of sufficient editing quality that they will be easily interpreted by the readership of the Journal. If submitted work does not meet this standard, it will be returned to the authors. The Journal follows the AMA Manual of Style for manuscripts submitted to biomedical journals.

Set your document as A4 paper, use double line spacing, Times font size 12, number all pages, do not justify the right margin, and do not use line numbers. Save your manuscript as a Word document (.doc, .docx, or previous).

Structure your manuscript file as follows: Title page, Abstract and key words, Text, Acknowledgments, References, Tables, Figure legends.

Title page. The first page (title page) of your manuscript file must include the following information:

- Full title (max 150 characters including letters and spaces), which must be concise and informative.
- Short title (max 75 characters, including letters and spaces).
- All authors listed as first name, initials, and last name (i.e., Zeynep Alkin, MD) with highest academic or medical degree first.
- Institutional affiliation of each author, using superscripts and not symbols (e.g., Alper Agca I).
- Corresponding author's information (full mailing address, phone and fax numbers, email address); this is usually the submitting author.
- Clinical trial protocol number when submitting a clinical trial protocol.
- Online-only supplementary material, with a short description.

Abstract. A structured abstract of no more than 350 words is to be provided, divided into the following sections: Objectives, Methods, Results, and Conclusion. Avoid abbreviations, diagrams, and reference to the text in the abstract. At least three and maximum of six key words should be identified for indexing. List the key words beneath the abstract in alphabetical order. Use terms from the Medical Subject Headings list from Index Medicus whenever possible. A library of terms is available at <http://www.nlm.nih.gov/mesh/meshhome.html>.

Main Text. Divide the text into the following sections: Introduction, Methods, Results, Discussion and Conclusion. Use commas (,) to separate thousands and full stop (.) for decimals (e.g. 12,354.55). Include tables in the manuscript file, after the references. Number all figures (graphs, charts, photographs, and illustrations) in the order of their citation in the text. Figures must be submitted as separate files and not embedded in the Word document.

Funding. List all sources of funding for the research.

Declaration of Interests. Declare any competing interests for each author. All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. It is the sole responsibility of authors to disclose any affiliation with any organization with a financial interest, direct or indirect, in the subject matter or materials discussed in the manuscript (such as consultancies, employment, paid expert testimony, honoraria, speakers bureaus, retainers, stock options or ownership, patents or patent applications or travel grants) that may affect the conduct or reporting of the work submitted. All sources of funding for research are to be explicitly stated. If uncertain as to what might be considered a potential conflict of interest, authors should err on the side of full disclosure.

All submissions to the journal must include full disclosure of all relationships that could be viewed as presenting a potential conflict of interest. If there are no conflicts of interest, authors should state that there are none. This must be stated at the point of submission (within the manuscript after the main text under a subheading "Declaration of interest" and where available within the appropriate field on the journal's Manuscript Central site). This may be made available to reviewers and will appear in the published article at the discretion of the Editors or Publisher.

If no conflict is declared, the following statement will be attached to all articles: Declaration of interest. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

The intent of this policy is not to prevent authors with these relationships from publishing work, but rather to adopt transparency such that readers can make objective judgments on conclusions drawn.

Acknowledgments.

List in this section:

- Any substantial contribution provided by a person other than the author and who does not fulfill authorship criteria
- The assistance of medical writing experts
- All participating group authors who do not meet the full authorship criteria
- All sources of funding for the manuscript and the financial disclosures for all authors

Written permission must be obtained to include the names of all individuals included in the Acknowledgments section.

If the manuscript has been presented at a meeting, please indicate in this section name, location, and date of event.

References. References should be identified in the text with Arabic numerals and numbered in the order cited. All references should be compiled at the end of the article in the Vancouver style.

Authors are responsible for the accuracy and completeness of their references and for correct text citation. Personal communications,

unpublished data, abstracts, and oral or poster presentations should be limited and incorporated in parentheses within the text without a reference number. Signed permission should be included from each individual identified in a personal communication or as a source for unpublished data, as well as the date of communication.

Authors are responsible for the accuracy and completeness of their references and for correct text citation. Personal communications, unpublished data, abstracts, and oral or poster presentations should be limited and incorporated in parentheses within the text without a reference number. A signed permission should be included from each individual identified in a personal communication or as a source for unpublished data, as well as the date of communication.

- References should follow the text and begin on a separate page.
- References must be double line spaced and numbered consecutively in order of appearance within the text, using the Word automated numbering tool.
- Identify references in text, tables, and legends with Arabic numerals in parentheses, i.e., (5).
- List all authors when six or fewer; when seven or more, list only the first three and add et al.
- References used within tables or figure legends should be included in the reference list and numbered in consecutive order according to the table/figure citation in the text.
- Journal names should be abbreviated according to Index Medicus/Medline. If there is any doubt about abbreviation of a journal name, it should be spelled out completely.
- Any references to studies (including books or articles) that have been accepted for publication but are not yet published should indicate where they will be published and have the term "in press" in the reference in place of volume and page numbers. These must be updated prior to publication, if possible.

Examples.

Journal article (print): Erdogan G, Unlu C, Gunay BO, Kardes E, Ergin A. Implantation of foldable posterior chamber intraocular lens in aphakic vitrectomized eyes without capsular support. *Arq Bras Oftalmol* 2016;79:159-62.

Journal article (print, more than six authors): Ozkaya A, Alagoz C, Garip R, et al. The role of indocyanine angiography imaging in further differential diagnosis of patients with nAMD who are morphologically poor responders to ranibizumab in a real-life setting. *Eye (Lond)* 2016;30:958-65.

Book: Bill A, Maepa O. Mechanisms and Routes of Aqueous Humor Drainage. Philadelphia: WB Saunders; 1975.

Contribution to a Book: Farris RL. Abnormalities of the tears and treatment of dry eyes. In: Kaufman HE, Barron BA, McDonald MB, editors. *The Cornea*. 2nd ed. Boston, MA: Butterworth-Heinemann; 1998.

Tables and Figures. Tables and figures should not be embedded in the text, but should be included as separate sheets or files. A short descriptive title should appear above each table with a clear legend and any footnotes suitably identified below. All units must be included. Figures should be completely labeled, taking into account necessary size reduction.

Captions should be typed, double-spaced, on a separate sheet. All original figures should be clearly marked with the number, author's name, and top edge indicated.

Illustrations. Illustrations submitted should be clean originals or digital files. Digital files are recommended for highest quality reproduction and should follow these guidelines:

300 dpi or higher sized to fit on journal page EPS, TIFF, or PSD format only submitted as separate files, not embedded in text files

Page Proofs: All proofs must be corrected and returned to the publisher within 48 hours of receipt. If the manuscript is not returned within the allotted time, the editor will proofread the article and it will be printed per the editor's instruction.



Ethics and Policies

Ethical Responsibilities and Policies

Publication Ethics

The Beyoglu Eye Journal applies standards throughout the publication process to further our goal of sharing high-quality, objective, reliable, and useful information. We implement these processes to ensure appropriate support for our authors and their institutions, as well as our readers. It is crucial that all of the stakeholders in the process (authors, readers and researchers, publishers, reviewers, and editors) comply with ethical principles.

The Beyoglu Eye Journal is an open access publication and follows the guidelines and policies published by the Committee on Publication Ethics (COPE) (<https://publicationethics.org>). We expect all participants to observe the ethical responsibilities presented below.

Author's Responsibilities

- Studies submitted for publication must be original works of the author. References to other studies must be cited and/or quoted completely and accurately;
- Only those who provide a substantial intellectual contribution to the content of the work may be cited as an author. Other contributors may be recognized with acknowledgements at the conclusion of the article;
- Competing interests or relationships that may constitute a conflict of interest must be declared and explained in all studies submitted for publication;
- Authors must be able to provide documentation showing that they have the right to use the data analyzed, the necessary permissions related to the research, and any appropriate consent;
- Raw data used in the article must be available and may be requested from the author(s) within the framework of the evaluation process;
- In the event the author(s) notice an error at any point in the publication process or after publication, they have the obligation to inform the journal editor or publisher and cooperate in appropriate corrective action;
- Authors may not submit their article for publication to more than one journal simultaneously. Each application must be initiated following the completion of any previous effort. The Beyoglu Eye Journal will not accept previously published articles;
- Changes in authorship designation (such as adding authors, changing the printed order of the authors, removing an author) once the evaluation process has begun will not be accepted in order to protect all parties involved.

Editor's Role and Responsibilities

General Duties

The editor is responsible for everything published in the journal. In the context of this responsibility, editors have the following duties and obligations:

- Endeavor to meet the needs of readers and authors;
- Maintain continuous development to improve the quality of the journal;
- Consistently work to ensure quality;
- Support freedom of thought;
- Ensure academic integrity;
- Prevent business needs from compromising intellectual and ethical standards;
- Demonstrate clarity and transparency with any necessary corrections or explanations.

Reader Relationship

The editor is to make publication decisions based on expectations of suitable and desirable material. Studies accepted for publication must be original contributions that benefit the reader, researcher, practitioner, and the literature. In addition, editors are obliged to take into account feedback from readers, researchers, and practitioners, and to provide an informative response. Readers will also be informed of any funding provided to support published research.

Author Relationship

- The decision to accept an article is to be based on the importance, original value, validity, and clarity of expression of the work, and the goals and objectives of the journal;
- Studies accepted for evaluation and publication will not be withdrawn unless serious problems are identified;
- The editor will not disregard positive reviewer comments unless there is a serious problem with the study;
- New editors will not change publishing decisions made by previous editor(s) unless there is a serious problem;
- A description of the submission and evaluation process is publicly available;
- Authors are provided with descriptive and informative feedback.

Reviewer Relationship

- Reviewers are to be selected according to the subject of the study;
- Information and guidance for the evaluation phase is provided;
- Any conflicts of interest between authors and reviewers will be disclosed and managed appropriately;
- Reviewer identity is to be kept confidential to preserve a blind review process;
- Reviewers are to evaluate the study using unbiased, scientific, and constructive comments. Unkind or unscientific commentary will not be permitted;
- Reviewers will be evaluated using criteria such as timely response and quality of observations;
- The pool of reviewers is to be assessed and supplemented regularly to ensure a broad scope of expertise.

Editorial Board Relationship

The editor works with the members of the editorial board to ensure that they are familiar with journal policies and developments in regular meetings and announcements, and will provide training for new members and assistance to board members during their tenure in their role as a supporter of the journal.

- Editorial board members must be qualified and able to contribute to the journal;
- Members of the editorial board must evaluate studies impartially and independently;
- Editorial board members with the appropriate expertise will be given the opportunity to evaluate suitable articles;
- The editor will maintain regular contact with the editorial board and hold regular meetings regarding the development of editorial policies and other aspects of journal management.

Relations with the Owner of the Journal and the Publisher

The relationship between the editors and the publisher/journal owner is based on the principle of editorial independence and stipulated by contract.

Editorial and Blind Review Processes

The editor will apply the publicly defined publication policies created and enforced to ensure a timely and impartial evaluation process for all submissions.

Quality Assurance

The editor is responsible for confirming that the The Beyoglu Eye Journal publishing policies and standards are upheld for all articles.

Protection of Personal Data

The editor is obliged to ensure the protection of personal data related to subjects or images included in published work. Explicit documented consent of the individuals referenced in the research is required before the study will be accepted. The editors is also responsible for protecting the individual data of authors, reviewers, and readers.

Ethics Committee, Human and Animal Rights

The editor is required to ensure that human and animal rights were protected in the studies submitted for publication.

Measures Against Potential Misconduct

The editor must take action against any allegations of possible misconduct. In addition to conducting a rigorous and objective investigation of complaints, the editor is expected to share the findings and conclusions.

Maintaining Academic Publication Integrity

The editor is expected to ensure that any errors, inconsistencies, or misleading statements are corrected quickly and appropriately acknowledged.

Protection of Intellectual Property Rights

The editor is obliged to protect intellectual property and to defend the rights of the journal and author(s). In addition, the editor is to take the necessary measures to prevent any violation of the intellectual property rights of others in journal publications.

Creativity and Openness

- Constructive criticism is to be encouraged;
- Authors will be given the opportunity to reply to criticism;
- Negative results will not be a reason for submission denial.

Complaints

Editors are to respond to all complaints in a timely and comprehensive manner.

Political and Commercial Concerns

Political or commercial factors will not affect editorial decisions.

Conflicts of Interest

The editor is required to ensure that any conflicts of interest between authors, reviewers, or other editors are disclosed and managed appropriately to provide an independent and impartial process.

Reviewer's Ethical Responsibilities

Peer review of research embodies the scientific method, subjecting the work to the rigorous scrutiny of knowledgeable colleagues. The rigor of the review process directly affects the quality of the literature; it provides confidence in an objective and independent evaluation of the published work. The Beyoglu Eye Journal uses a double-blind review process. All comments and the evaluation are transmitted through the journal management system. Reviewers should:

- Only agree to evaluate studies related to their specialty;
- Return reviews within the designated timeframe;
- Evaluate with impartiality. Nationality, gender, religious beliefs, political beliefs, commercial concerns, or other considerations must not influence the evaluation;
- Refuse to review any work with a potential conflict of interest and inform the journal editor;
- Maintain confidentiality of all information. Only the final published version may be used for any purpose;
- Use thoughtful and constructive language. Hostile or derogatory comments are not acceptable;
- Report any potentially unethical behavior or content to kare@karepb.com via e-mail.



ORIGINAL ARTICLES

- A Decade of Evisceration: Investigating the Influence of Demographic, Clinical, and Psychosocial Factors**
Serbest Ceylanoglu K, Altas FB, Sen E, Corak Eroglu F, Yenigun S..... 115
- Long-Term Structural Changes Observed on Gonioscopy and Anterior-Segment OCT Following Gonioscopy-Assisted Transluminal Trabeculotomy**
Alagoz N, Cakir I, Altan C, Bozkurt E, Ipekli Z, Erdogdu E, et al 120
- Evaluation of Peripapillary Choroidal Thickness, Retinal Nerve Fiber Layer, and Optic Nerve Head Parameters in Patients with Multiple Sclerosis**
Garli M, Aydin Kurna S, Gozke E, Parasiz Yukselen N..... 128
- Frequency of ROP Diagnosis and Treatment in Very Low Birth Weight Preterm Infants by Gestational Week and Birth Weight: A Single-Center Experience**
Gül C, Karapapak M..... 137
- Evaluation of Choroidal Structures in Children with Newly Diagnosed Type-1 Diabetes Mellitus**
Bilici S, Gultekin Erol T, Bilici ME, Canturk Ugurbas S, Ugurbas SH..... 144
- A Comprehensive Evaluation of Serum Iron Status Indicators in Patients with Age-Related Macular Degeneration**
Onder Tokuc E, Seyyar SA, Basaran E, Ozdemir SN, Karabas L..... 149
- CASE REPORT**
- Orbital Metastasis from Breast Cancer: Three Cases and Brief Review of the Literature**
Ciftci MD, Serin G, Ceylan N, Yeniay L, Palamar M..... 155
- Ocular Surface Squamous Neoplasia in Renal Transplant Patients**
Kaplan A, Akalin T, Palamar M 161
- The Relevance of Bacillary Layer Detachment and Choroidal flow Insufficiency in Unilateral Acute Idiopathic Maculopathy Associated with Hand, Foot, and Mouth Disease: A Case Report**
Thakur R, Guleser UY, Kesim C, Kapran Z, Tugal-Tutkun I, Hasanreisoglu M..... 165
- Foveal Hypoplasia in Presumed Xeroderma Pigmentosum: A Case Report**
Karatat E, Utine CA, Lebe B, Kaya M..... 172